Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes — [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [18F]FDG PET/CT qualification in Polish multicentre experience — do we need [18F]FDG PET/CT for qualification to PRRT?
INTRODUCTION: Peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues is a treatment option for patients with disseminated neuroendocrine tumours (NET). The aim of the study was the evaluation of the role of [¹⁸F]FDG PET/CT in predicting response, progression-free sur...
Na minha lista:
| Principais autores: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Via Medica
2020-06-01
|
| coleção: | Endokrynologia Polska |
| Assuntos: | |
| Acesso em linha: | https://journals.viamedica.pl/endokrynologia_polska/article/view/67499 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|